Download MendeleyAntigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153.
Paciello, I., Rundlet, E.J., Zhou, L., Realini, G., Perrone, F., Pierleoni, G., Troisi, M., Postal, J., Guivel-Benhassine, F., Porrot, F., Mullins, C.M., Moschese, D., Cossu, M.V., Sabaini, F., Accordini, S., Gianesini, N., Passarelli Mantovani, R., Panza, F., Fabbiani, M., Tumbarello, M., Antinori, S., Castilletti, C., Montagnani, F., Schwartz, O., Rappuoli, R., McLellan, J.S., Andreano, E.(2025) Sci Transl Med 17: eaeb3840-eaeb3840
- PubMed: 41370398
- DOI: https://doi.org/10.1126/scitranslmed.aeb3840
- Primary Citation of Related Structures:
9OG1, 9OG2 - PubMed Abstract:
Recurrent mpox outbreaks caused by the monkeypox virus (MPXV) have prompted the World Health Organization to declare a Public Health Emergency of International Concern and have stimulated the development of medical interventions. Here, we used antigen-agnostic identification of MPXV-neutralizing monoclonal antibodies from convalescent or vaccinated people, AlphaFold 3-based predictive modeling, and cryo-electron microscopy to identify the protein encoded by orthopoxviral gene (OPG) 153 (MPXV A28) as a target of broadly neutralizing antibodies. OPG153-targeting antibodies neutralized MPXV clades Ib and IIb and vaccinia virus (VACV) and cross-reacted with OPG153 orthologs from cowpox and variola viruses. Immunization with MPXV OPG153 elicited a potent neutralizing antibody response against MPXV and VACV in mice, substantiating OPG153 as both a promising vaccine antigen and a potent target for preventive and therapeutic antibodies.
- Monoclonal Antibody Discovery (MAD) Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Organizational Affiliation:
